A Phase 2 interventional study of pegfilgrastim 12 mg and filgrastim in Lymphoma, Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-28.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pegfilgrastim in Lymphoma — none open to participants now, 1 under way, none of them phase 3. pegfilgrastim · Lymphoma.
Among the 13 studies testing pegfilgrastim in Lymphoma, this one is the 7th largest by enrollment, is the only one that started in 2003, is one of 8 in phase 2, and was the 3rd registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 13 studies testing pegfilgrastim in Lymphoma is open now. The open studies under Lymphoma, anywhere →
pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 2
First in 2000; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 41 across the 13 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
13 studies in Lymphoma by Amgen: none open now, none under way, none of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 13 studies in Lymphoma by Amgen, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2003, is one of 6 in phase 2, and was the 3rd registered.
Amgen’s Lymphoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing pegfilgrastim in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 13 in Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.
This is a research study for Hodgkin's Disease and Non-Hodgkin's Lymphoma (NHL) patients who will receive high-dose chemotherapy with autologous peripheral blood stem cell (PBSC or PBPC) transplant. The chemotherapy doses are high enough to severely suppress the bone marrow (where blood cells are made) and cause very low blood counts. A collection of stem cells (very young blood cells) followed by reinfusion to restore blood counts will be done to stimulate recovery of your blood counts. This procedure is called leukapheresis. Giving growth factors to patients is a method to increase the number of PBPC that can be collected during leukapheresis. This process of giving growth factors to patients is called mobilization (moving cells from the bone marrow to the peripheral blood where they can be collected). The purpose of this study is to determine if pegfilgrastim, an investigational drug, can safely and effectively mobilize stem cells. Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization. Pegfilgrastim is a modified version of Filgrastim that is longer acting.
Pegfilgrastim 6 mg given once for PBPC mobilization
Drug: pegfilgrastim 6 mg
Pegfilgrastim 12 mg given once for PBPC mobilization
Drug: pegfilgrastim 12 mg
Filgrastim given daily for PBPC mobilization
Drug: filgrastim
Pegfilgrastim 12 mg given once for PBPC mobilization
Filgrastim given daily for PBPC mobilization
Pegfilgrastim 6 mg given once for PBPC mobilization
CD34+ collection during the collection phase
Time frame: 10 days
Time to ANC and platelet engraftment post-transplant
Time frame: 100 days
No study locations are listed for this record.
The record gives a start of Apr 2003, a primary completion of Mar 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim